Johnson & Johnson (JNJ)
More Upside For JNJ Stock In 2026?
Johnson & Johnson has just undergone its most significant transformation in decades. In 2023, the consumer health segment was spun off as Kenvue.
Can J&J's Pipeline Progress in 2025 Aid Long-Term Growth?
JNJ's rapidly advancing pipeline, new drug approvals and expanding cancer and neuroscience portfolio could fuel growth through the next decade.
J&J ordered to pay record $1.5B in talc cancer lawsuit — while vowing to appeal ‘unconstitutional' ruling
The plaintiff's law firm said was the largest-ever sum awarded against J&J for a single plaintiff.
JNJ's Tremfya Gets EU Approval for Pediatric Plaque Psoriasis
Johnson & Johnson wins EU approval for Tremfya in pediatric plaque psoriasis, making it the first IL-23 inhibitor cleared for any pediatric condition.
Stormy 2026? 3 Defensive Stocks to Weather a Recession
TPB, JNJ and NEE highlight how defensive stocks can offer stability and steady growth potential amid rising uncertainty for 2026.
J&J Wins FDA Nod for Subcutaneous Version of NSCLC Drug Rybrevant (Revised)
JNJ wins FDA approval for a subcutaneous version of Rybrevant, cutting treatment time to minutes and boosting convenience across NSCLC indications.
J&J vows appeal after US jury hits it with record $1.5 billion talc cancer award
A Baltimore jury ordered Johnson & Johnson and its subsidiaries to pay over $1.5 billion to a woman who claimed decades of exposure to asbestos in the company's talc-based products caused her peritoneal mesothelioma, a form of cancer.
J&J Stock Trading Above 50- & 200-Day SMA for 6 Months: How to Play
J&J has been trading above its 50- and 200-day SMAs for six months as strong 2025 execution, new drugs and pipeline progress support bullish momentum.
Minnesota jury says Johnson & Johnson owes $65.5 million to woman with cancer who used talcum powder
A Minnesota jury awarded $65.5 million on Friday to a mother of three who claimed talcum products made by Johnson & Johnson exposed her to asbestos and contributed to her developing cancer in the lining of her lungs.
J&J Wins FDA Nod for Subcutaneous Version of NSCLC Drug Rybrevant
JNJ wins FDA approval for a subcutaneous version of Rybrevant, cutting treatment time to minutes and boosting convenience across NSCLC indications.
Johnson & Johnson: Valuation Premium Justified By Accelerating Growth And Mix Premiumization
Johnson & Johnson is rated a buy, with accelerating revenue and earnings growth driven by TREMFYA, CARVYKTI, and robust MedTech innovation. JNJ's portfolio reshaping (divesting Orthopaedics and focusing on premium cardiovascular and vision franchises) should enhance margins and long-term growth prospects. TREMFYA's rapid adoption in IBD and the anticipated 2026 launch of icotrokinra position JNJ for continued immunology growth despite STELARA's LOE.
Is Trending Stock Johnson & Johnson (JNJ) a Buy Now?
Zacks.com users have recently been watching Johnson & Johnson (JNJ) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
